Abstract:Background To investigate the impact of initial antifungal therapeutic strategies on the prognosis of invasive Candida infections (ICIs) in intensive care units (ICUs) in China. Methods A total of 306 patients with proven ICIs in the China-SCAN study were analyzed retrospectively. Empiric, pre-emptive, and targeted therapy were adopted based on starting criteria including clinical, microbiological, and other conventional prediction rules. The primary outcome was hospital mortality and the secondary endpoints were duration days in ICU and duration days in hospital. The global responses (clinical and microbiological) at the end of the empirical therapy were also assessed. Results A total of 268/306 (87.6%) ICI patients received antifungal therapy, including 142/268 (53.0%) initial empirical therapy, 53/268 (19.8%) initial pre-emptive therapy, and 73/268 (27.2%) initial targeted therapy. Compared with the initial empirical antifungal therapy and targeted antifungal therapy, patients with initial pre-emptive antifungal therapy had significantly less clinical remission [11/53 (21.2%) vs . 61/142 (43.3%) vs . 22/73 (30.1%), P = 0.009], higher ICU [26/53 (57.8%) vs . 42/142 (32.2%) vs . 27/73 (43.5%), P = 0.008] and hospital mortality [27/53 (60.0%) vs . 43/142 (32.8%) vs . 29/73 (46.8%), P = 0.004] and more microbiological persistence [9/53 (17.0%) vs . 6/142 (4.2%) vs . 9/73 (12.3%), P = 0.011]. Kaplan-Meier survival analysis revealed that ICI patients with initial pre-emptive antifungal therapy and targeted antifungal therapy were associated with reduced hospital duration compared with patients with initial empirical antifungal therapy after confirmation of fungal infection (log-rank test: P = 0.021). Multivariate regression analysis provided evidence that initial empirical antifungal therapy was an independent predictor for DECREASING the hospital mortality in ICI patients on ICU admission and at ICI diagnosis (odds ratio 0.327, 95% confidence interval 0.160–0.667, P = 0.002; odds ratio 0.351, 95% confidence interval 0.168–0.735, P = 0.006). Conclusions The initial therapeutic strategy for invasive candidiasis was independently associated with hospital mortality. Prompt empirical antifungal therapy could be critical to decrease early hospital mortality. Trial registration Clinicaltrials.gov NCT01253954 (retrospectively registration date: December 3, 2010)

Cost-Effectiveness Analysis of Caspofungin Versus Voriconazole in the Empirical Antifungal Therapy of Febrile Neutropenia in China

Economic Evaluation of Caspofungin vs. Voriconazole in Initial Empirical Antifungal Therapy of Febrile Neutropenia

Efficacy and Safety of Itraconazole As Empirical Antifungal Therapy in Febrile Neutropenic Patients with Hematologic Malignancies: an Open-Lable, Multicenter, Observational Trial in A Chinese Cohort

Distribution and Antifungal Susceptibility of Candida Species Causing Candidemia in China: an Update from the CHIF-NET Study

Posaconazole Vs. Fluconazole As Invasive Fungal Infection Prophylaxis in China: A Multicenter, Randomized, Open-Label Study

Empiric Treatment Against Invasive Fungal Diseases in Febrile Neutropenic Patients: a Systematic Review and Network Meta-Analysis

Efficacy of Caspofungin Combined with Trimethoprim/sulfamethoxazole As First-Line Therapy to Treat Non-Hiv Patients with Severe Pneumocystis Pneumonia.

Pharmacoeconomic evaluation of micafungin versus caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in Turkey

Efficacy of Caspofungin in Unclassified Invasive Fungal Infection Cases: A Retrospective Analysis of Patients with Hematological Malignancies in China.

Real-world assessment of the effectiveness of posaconazole for the prophylaxis and treatment of invasive fungal infections in hematological patients A retrospective observational study

Impact of Initial Empirical Antifungal Agents on the Outcome of Critically Ill Patients with Invasive Candidiasis: Analysis of the China-SCAN Study

Caspofungin Treatment for Pulmonary Invasive Fungal Disease in Hematology Patients: A Retrospective Study in A Clinical Practice Setting in China

Invasive Candidiasis in Intensive Care Units in China: a Multicentre Prospective Observational Study

Invasive Candidiasis in Intensive Care Units in China: in Vitro Antifungal Susceptibility in the China-SCAN Study

Network meta-analysis of triazole, polyene, and echinocandin antifungal agents in invasive fungal infection prophylaxis in patients with hematological malignancies

Impact of risk stratification on the duration of caspofungin therapy for invasive fungal disease in acute leukemic patients.

The Efficacy of CT-Diagnostic-Driven Antifungal Strategy with Voriconazole for Invasive Aspergillosis in Patients with Hematological Diseases: A Multicenter, Prospective Study

Cross-sectional Investigation of First-Choice of Antifungal Agents in Empirical and Preemptive Antifungal Therapy for Patients with Hematological Malignancies

Economic Evaluation of Posaconazole Versus Fluconazole or Itraconazole in the Prevention of Invasive Fungal Infection in High-Risk Neutropenic Patients in Sweden

Initial therapeutic strategy of invasive candidiasis for intensive care unit patients: a retrospective analysis from the China-SCAN study

Efficacy of the Combination of Voriconazole and Caspofungin in Experimental Pulmonary Aspergillosis by Different Aspergillus Species